Indications and uses
Fluorescein Injection 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. (1)
Fluorescein Injection 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. (1)
Adult Dose The recommended dosage of Fluorescein Injection 10% (100 mg/mL) is 500 mg via intravenous administration. Pediatric Dose For children, the dose is 7.7 mg/kg (actual body weight) up to a maximum of 500 mg, via intravenous infusion calculated on the basis of 35 mg for each 4.54 kg of body weight. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to admini...
Fluorescein Injection, USP 10%, 500 mg/5 mL (100 mg/mL) of fluorescein sodium is a dark reddish orange, clear solution in a single-dose vial. (NDC 54288-179-10) 5 mL, single dose vials in a package of 10. Store fluorescein injection at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Discard unused portion.
Fluorescein Injection 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. (1)
Adult Dose
The recommended dosage of Fluorescein Injection 10% (100 mg/mL) is 500 mg via intravenous administration.
Pediatric Dose
For children, the dose is 7.7 mg/kg (actual body weight) up to a maximum of 500 mg, via intravenous infusion calculated on the basis of 35 mg for each 4.54 kg of body weight.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not mix or dilute with other solutions or drugs.Discard unused portion.
Inject the dose (over 5-10 seconds is normally recommended) into the antecubital vein, after taking precautions to avoid extravasation. A syringe, filled with Fluorescein, may be attached to transparent tubing and a 23 gauge butterfly needle for injection. Insert the needle and draw the patient's blood to the hub of the syringe so that a small air bubble separates the patient's blood in the tubing from the fluorescein. With the room lights on, slowly inject the blood back into the vein while watching the skin over the needle tip. If the needle has extravasated, the patient's blood will be seen to bulge the skin and the injection should be stopped before any fluorescein is injected. When assured that extravasation has not occurred, the room light may be turned off and the fluorescein injection completed. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds and can be observed by standard viewing equipment.
Reduction in dose from 500 mg to 200 mg of Fluorescein Injection, 10% may be appropriate in cases when a highly sensitive imaging system e.g., scanning laser ophthalmoscope is used.
Injection:
Fluorescein Injection is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)].
Caution should be exercised in patients with a history of allergy or bronchial asthma. An emergency tray should always be available.
If a potential allergy is suspected, an intradermal skin test may be performed prior to intravenous administration, i.e., 0.05 mL injected intradermally to be evaluated 30 to 60 minutes following injection. Given the sensitivity and specificity of skin testing, a negative skin test is not proof that a patient is not allergic to fluorescein.
Extravasation during injection can result in severe local tissue damage due to high pH of fluorescein solution. The following complications resulting from extravasation of fluorescein have been noted to occur: Sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median nerve in the antecubital area. Complications resulting from extravasation can cause severe pain in the arm for up to several hours. When extravasation occurs, the injection should be discontinued and conservative measures to treat damaged tissue and to relieve pain should be implemented. [see Administration (2.3 ) and Adverse Reactions (6.6)].
The most common reaction is discoloration of the skin and urine. Skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours.
The next most common adverse reaction is nausea. Vomiting, and gastrointestinal distress have also occurred. A strong taste may develop after injection.
Syncope and hypotension may occur. Cardiac arrest, basilar artery ischemia, severe shock and death may occur rarely. [see W arnings and Precautions (5.1)]
Headache may occur. Convulsions may rarely occur following injection.
Pregnancy Category C. Adequate animal reproduction studies have not been conducted with fluorescein sodium. It is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. Fluorescein sodium should be given to a pregnant woman only if clearly needed.
Fluorescein sodium has been demonstrated to be excreted in human milk. Caution should be exercised when fluorescein sodium is administered to a nursing woman.
Pediatric patients have been included in clinical studies. No overall differences in safety or effectiveness have been observed between pediatric and adult patients.
No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
Fluorescein Injection, USP contains fluorescein sodium, a diagnostic aid, in a sterile solution for use intravenously. It is a dark reddish orange clear solution with a pH of 8.3 to 9.8 and an osmolality of 572 to 858 mOsm/kg.
Its chemical name is spiro[isobenzofuran-1 (3H),9'-[9H]xanthene]-3-one,3'6'- dihydroxy, disodium salt. Its molecular weight is 376.27. The active ingredient is represented by the chemical structure:
Fluorescein Injection, USP 500 mg/5 mL (100 mg/mL) 10% contains:
Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures.
Distribution.
Within 7 to 14 seconds after IV administration into the antecubital vein, fluorescein usually appears in the central retinal artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade 6 to 12 hours after dosing. Various estimates of volume of distribution indicate that fluorescein distributes into interstitial space (0.5 L/kg).
Metabolism.
Fluorescein is metabolized to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose.
Excretion.
Fluorescein and its metabolite are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.
There have been no long-term studies done using fluorescein in animals to evaluate carcinogenic potential.
Fluorescein Injection, USP 10%, 500 mg/5 mL (100 mg/mL) of fluorescein sodium is a dark reddish orange, clear solution in a single-dose vial.
(NDC 54288-179-10) 5 mL, single dose vials in a package of 10.
Store fluorescein injection at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Discard unused portion.
After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [see Warnings and Precautions (6.1)].
Rx only
Manufactured by:
BPI Labs, LLC
12393 Belcher Road S, Suite 450
Largo, FL 33773 USA
LI69I
R-2605
Revised: May 2026
Principal Display Panel – 5 mL Carton Label
NDC 54288-179-10
Rx Only
Fluorescein Injection, USP 10%
500 mg/5 mL (100 mg/mL) / 10x5 mL sterile Single-dose Vials
Principal Display Panel – 5 mL Label
NDC 54288-179-01
Rx Only
Fluorescein Injection, USP 10% 500 mg/5 mL (100 mg/mL)
| Class | Version | Type | Effective |
|---|---|---|---|
| FLUORESCEIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0354288179010 | GTIN-13: 0354288179010 EAN-13: 0354288179010 GTIN-12: 354288179010 UPC-A: 354288179010 GTIN storage (14 digits): 00354288179010 | Container Label.jpg |
| Barcode | EAN-13 | 0354288179102 | GTIN-13: 0354288179102 EAN-13: 0354288179102 GTIN-12: 354288179102 UPC-A: 354288179102 GTIN storage (14 digits): 00354288179102 | LI179C-10_R-2605_QC_v1_Page_1.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 8f43a274-9585-47cb-b427-0eb3e578384d | Product name | 1 | 20250623 |
| 4a998fa9-995e-4ea5-97ef-93a559305758 | Product name | 1 | 20200706 |
| c94ccba7-2a03-4a3e-a891-d62a57340fb2 | Product name | 1 | 20180215 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 54288-179-01 | Fluorescein | 5 mL in 1 VIAL, GLASS | INJECTION, SOLUTION | 5 | 1 | |
| 54288-179-10 | Fluorescein | 10 in 1 CARTON | INJECTION, SOLUTION | 10 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 54288-179 | 54288-179-01, 54288-179-10 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| fluorescein sodium | 93X55PE38X | ACTIB |
| sodium hydroxide | 55X04QC32I | IACT |
| hydrochloric acid | QTT17582CB | IACT |
| water | 059QF0KO0R | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A220046-001 | FLUORESCEIN SODIUM | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-04-30 |
| Application-product | TE code |
|---|---|
| A220046-001 | AP |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A220046-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-04-30 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A220046-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-04-30 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A220046-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-04-30 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A220046-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-04-30 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A220046-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-04-30 | a50c72e98297… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A220046-001 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A220046-001 | AP | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A220046-001 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A220046-001 | AP | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A220046-001 | AP | 1 | a50c72e98297… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Fluorescein | FLUORESCEIN | BPI Labs LLC | 770582e3-c99b-4a02-868c-29309013717e | 2026-05-01 | Warnings, Adverse reactions | 54288-179-01 54288-179-10 54288-179 54288017901 54288017910 5b9c9100-13f7-4eab-a770-339aa885a949 770582e3-c99b-4a02-868c-29309013717e |
Adverse event summaries are temporarily unavailable. Other product information remains available.